Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Intratumoral cancer therapies are designed to deliver treatment directly into accessible tumors, supporting stronger local activity with reduced systemic exposure. The addressable population spans melanoma, bladder cancer, head and neck cancer, breast cancer, and selected sarcomas. GLOBOCAN 2024 reported 337,969 melanoma cases and 635,264 bladder cancer cases worldwide. The Intratumoral Cancer Therapies pipeline analysis by Expert Market Research highlights progress in oncolytic viruses, cytokines, immune stimulants, and combination regimens aimed at improving durable responses across difficult-to-treat solid tumors globally.
-
Major companies involved in the intratumoral cancer therapies pipeline analysis include Onchilles Pharma Inc., Vaxiion Therapeutics, and others.
-
Leading drugs currently in the pipeline include L19IL2/L19TNF, OH2+BS006, and others.
-
The pipeline is advancing through engineered oncolytic viruses, immunocytokines, and localized immune agonists that remodel the tumor microenvironment while minimizing systemic toxicity. Increasing integration with checkpoint inhibitors, image-guided delivery technologies, and biomarker-driven patient selection is expanding therapeutic potential and accelerating differentiated clinical development across solid tumor indications.
Report Coverage
The Intratumoral Cancer Therapies Pipeline Analysis Report by Expert Market Research gives comprehensive insights into intratumoral cancer therapies therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for intratumoral cancer therapies. The intratumoral cancer therapies report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The intratumoral cancer therapies pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with intratumoral cancer therapies treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to intratumoral cancer therapies.
Read more about this report - Request a Free Sample
Intratumoral Cancer Therapies Pipeline Outlook
Intratumoral cancer therapies pipeline outlook remains promising, driven by advances in localized drug delivery and immune activation strategies. In September 2025, the U.S. FDA approved INLEXZO, an intravesical gemcitabine system, highlighting growing interest in site-specific treatments that enhance efficacy while limiting systemic toxicity. Ongoing trials are evaluating oncolytic viruses, cytokine-based agents, and combination regimens. Rising investment and innovation are expected to expand therapeutic options, improve patient outcomes, and accelerate precision-targeted intratumoral therapies across multiple cancer types in coming years.
Intratumoral Cancer Therapies Epidemiology
Intratumoral cancer therapies address patients with accessible solid tumors, particularly melanoma, bladder cancer, head and neck cancers, and selected breast or sarcoma lesions. GLOBOCAN 2024 estimated 337,969 new melanoma cases and 635,264 bladder cancer cases worldwide, with five-year prevalence reaching 1.31 million and 1.98 million, respectively. The eligible treatment population is narrower, shaped by tumor accessibility, disease stage, prior treatment, biomarker status, and suitability for localized immune stimulation or sustained site-directed drug delivery across routine oncology practice and clinical trials.
Intratumoral Cancer Therapies – Pipeline Therapeutic Assessment
This section of the report covers the analysis of intratumoral cancer therapies drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The intratumoral cancer therapies pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Oncolytic Viruses
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Intratumoral Cancer Therapies Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total intratumoral cancer therapies clinical trials. Early Phase I accounting for 3.45%, Phase I for 55.17%, Phase II for 34.48%, Phase III for 6.90%, and Phase IV for 0.00%, indicating a strong emphasis on early-stage clinical innovation and translational development in intratumoral cancer therapies.
Intratumoral Cancer Therapies Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the intratumoral cancer therapies pipeline analysis include small molecules, monoclonal antibodies, and oncolytic viruses. The intratumoral cancer therapies report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for intratumoral cancer therapies. In February 2024, the US FDA approved lifileucel (Amtagvi), an autologous tumor-infiltrating lymphocyte therapy, for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, if BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor.
Intratumoral Cancer Therapies Clinical Trials – Key Players
The EMR report for the intratumoral cancer therapies pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed intratumoral cancer therapies therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in intratumoral cancer therapies clinical trials:
- Coordination Pharmaceuticals, Inc.
- Presage Biosciences
- Onchilles Pharma Inc.
- Vaxiion Therapeutics
- Binhui Biopharmaceutical Co., Ltd.
- Philogen S.p.A.
- BioMed Valley Discoveries, Inc.
- Merck Sharp & Dohme LLC
- Onchilles Pharma Pty Ltd.
- Highlight Therapeutics
Intratumoral Cancer Therapies – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for intratumoral cancer therapies. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of intratumoral cancer therapies drug candidates.
Biological: N17350
N17350 is an investigational biological immunotherapy being developed by Nona Biosciences for intratumoral cancer therapies. The candidate is administered directly into tumors to stimulate localized immune activation, enhance antigen presentation, and promote systemic antitumor immune responses while minimizing off-target toxicity. The ongoing early-phase clinical study is expected to reach primary completion in 2027. Nona Biosciences specializes in antibody discovery and biologics development, leveraging advanced antibody engineering platforms to accelerate innovative oncology therapeutics.
Biological: OH2+BS006
OH2+BS006 is a combination biological therapy jointly developed by Binhui Biopharmaceuticals using the oncolytic herpes simplex virus OH2 with the investigational bispecific antibody BS006. Designed for intratumoral cancer therapies, it combines direct tumor cell lysis with enhanced T-cell activation to strengthen local and systemic antitumor immunity. The ongoing Phase I clinical study is expected to be completed in 2027. Binhui Biopharmaceuticals focuses on developing innovative oncolytic virus and immuno-oncology platforms for solid tumors.
Drug: L19IL2/L19TNF
L19IL2/L19TNF is an investigational immunocytokine combination developed by Philogen S.p.A. for intratumoral cancer therapies. It combines tumor-targeting antibodies with the cytokines interleukin-2 and tumor necrosis factor to selectively deliver immune-stimulating molecules into the tumor microenvironment, enhancing local immune responses while limiting systemic toxicity. Clinical studies are expected to reach completion in 2027. Philogen is an Italian biotechnology company recognized for developing antibody-based targeted therapeutics and precision immuno-oncology products.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Intratumoral Cancer Therapies Pipeline Insight Report
- Which companies/institutions are leading the intratumoral cancer therapies drug development?
- Which company is leading the intratumoral cancer therapies pipeline development activities?
- What is the current intratumoral cancer therapies commercial assessment?
- What are the opportunities and challenges present in the intratumoral cancer therapies pipeline landscape?
- What is the efficacy and safety profile of intratumoral cancer therapies pipeline drugs?
- Which company is conducting major trials for intratumoral cancer therapies drugs?
- Which companies/institutions are involved in intratumoral cancer therapies collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in intratumoral cancer therapies?
Reasons To Buy This Report
The Intratumoral Cancer Therapies Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for intratumoral cancer therapies. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into intratumoral cancer therapies collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
